TY  - JOUR

T1  - Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.

JO  - Pharmacoeconomics

PY  - 2013/04/12

AU  - Kearns B

AU  - Lloyd Jones M

AU  - Stevenson M

AU  - Littlewood C

ED  - 

DO  - DOI: 10.1007/s40273-013-0050-9

VL  - 31

IS  - 6

SP  - 479

EP  - 488

Y2  - 2025/02/05

ER  -